



(51) International Patent Classification:

C07D 413/14 (2006.01) *A61P 35/00* (2006.01)
A61K 31/496 (2006.01)

(21) International Application Number:

PCT/EP2013/052182

(22) International Filing Date:

4 February 2013 (04.02.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1202027.7 6 February 2012 (06.02.2012) GB

(71) Applicant: **SAREUM LIMITED** [GB/GB]; Unit 2A,
Langford Arch, London Road, Pampisford, Cambridge,
Cambridgeshire CB22 3FX (GB).

(72) Inventor: **READER, John Charles**; Unit 2A, Langford
Arch, London Road, Pampisford, Cambridge, Cambridge-
shire CB22 3FX (GB).

(74) Agent: **SCHLICH LLP**; 9 St Catherine's Road, Little-
hampton, Sussex BN17 5HS (GB).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: AURORA AND FLT3 KINASES MODULATORS



(1)

(57) Abstract: The invention provides a compound having the formula (1) useful as modulator of the activity of Aurora kinases and FLT3 kinases: and salts thereof; wherein: R^1 is hydrogen or C_{1-2} alkyl; and R^2 , R^3 and R^4 are the same or different and each is selected from hydrogen, C_{1-2} alkyl, fluorine, chlorine, C_{1-2} alkoxy and trifluoromethyl, provided that no more than two of R^2 , R^3 and R^4 are other than hydrogen. Also provided are pharmaceutical compositions containing the compounds and their use in medicine, and in particular in the treatment of cancer.